Compare Novartis AG (NVS) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Waste Management, Inc. — how do they compare? Novartis AG trades at $142.86 (market cap $268.57B), while Waste Management, Inc. trades at $209.6 (market cap $83.98B). The key difference: Novartis AG is far larger — about 3.2× Waste Management, Inc.'s market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Waste Management, Inc. for 130 Days on average.
| NVS | WM | |
|---|---|---|
Market Cap | $268.57B | $83.98B |
Volume | 1,532,573 | 2,182,180 |
Sector | Health | Industrials |
52-Week High | $168.62 | $246.51 |
52-Week Low | $121.80 | $196.77 |
Typical Hold Time | 82 Days | 130 Days |
Enterprise Value | $309.89B | $106.78B |
Dividend Yield | 3.31% | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% today, with mixed technical signals showing neutral momentum. The company demonstrates strong fundamentals with $56.67B revenue in 2025, 22.5% net margin, and consistent earnings beats in recent quarters. Recent developments include a significant $7.8B licensing deal with China's Abogen for mRNA therapy, though offset by clinical trial setbacks in ALS drug development and ongoing investor scrutiny of M&A strategy.
Outlook remains cautiously optimistic with analyst consensus target of $146 suggesting modest upside. Key opportunities include pipeline expansion through strategic partnerships, while risks involve clinical trial failures, M&A integration challenges, and patent cliff pressures. The stock presents a balanced risk-reward profile with strong profitability offset by pipeline execution concerns.
Waste Management (WM) trades at $208.94, up 0.51% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with $25.2B revenue in 2025, 11.12% net margin, and consistent earnings beats in recent quarters. Recent news highlights WM's defensive business model and dividend reliability, while analyst consensus remains strongly positive with 57% buy ratings.
WM presents a compelling long-term investment with stable cash flows and dividend growth potential, though elevated debt levels and near-term technical weakness warrant caution. The stock's premium valuation (P/E 29.55) reflects quality but limits near-term upside absent significant earnings acceleration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
